Goldman Sachs Resumes Gilead Sciences (GILD) at Neutral
Tweet
Share
E-mailGet Alerts GILD Hot Sheet
Price: $138.36 +0.16%
Rating Summary:
36 Buy, 7 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
36 Buy, 7 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Goldman Sachs resumes coverage on Gilead Sciences (NASDAQ: GILD) with a Neutral. PT $81.00.
The firm comments, "GILD's HIV franchise has been eclipsed by hepC in the recent dialogue. While we believe GILD’s single-tablet regimens will allow it to retain share in the HIV market beyond the patent "cliff" and believe ‘7977 for hepC will capture majority share, we see these opportunities as priced into shares."
For an analyst ratings summary and ratings history on Gilead Sciences click here. For more ratings news on Gilead Sciences click here.
Shares of Gilead Sciences closed at $76.23 yesterday.
The firm comments, "GILD's HIV franchise has been eclipsed by hepC in the recent dialogue. While we believe GILD’s single-tablet regimens will allow it to retain share in the HIV market beyond the patent "cliff" and believe ‘7977 for hepC will capture majority share, we see these opportunities as priced into shares."
For an analyst ratings summary and ratings history on Gilead Sciences click here. For more ratings news on Gilead Sciences click here.
Shares of Gilead Sciences closed at $76.23 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ICICI Securities Resumes Oberoi Realty Ltd (OBER:IN) at Buy (1)
- BMO Capital Resumes Snowline Gold Corp (SGD:CN) (SNWGF) at Outperform
- Raymond James Starts Polaryx Therapeutics (PLYX) at Strong Buy
Create E-mail Alert Related Categories
New CoverageRelated Entities
Goldman SachsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
